Amanta Healthcare Rating Upgraded Post-IPO, Debt Slashed Dramatically

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Amanta Healthcare Rating Upgraded Post-IPO, Debt Slashed Dramatically
Overview

Amanta Healthcare's bank facilities rating has been upgraded by CRISIL to BBB/Stable. This follows a significant improvement in its financial health after raising funds via an IPO. The company's debt levels have dramatically reduced, and it anticipates 8-10% revenue growth in FY26, with plans to achieve stable operating margins of 21-22% through capacity expansion.

Amanta Healthcare Sees Rating Upgrade on Strong Financial Turnaround Post-IPO

Amanta Healthcare Ltd. has received a significant boost to its creditworthiness, with CRISIL Ratings upgrading its long-term bank facilities rating to Crisil BBB/Stable and short-term facilities to Crisil A3+. This upgrade marks a pivotal moment for the company, underscoring a dramatic improvement in its financial health, primarily driven by the successful completion of its Initial Public Offering (IPO).

The Backstory: IPO Fuels Financial Fortitude

The company recently raised approximately ₹126 crore through its IPO. The primary objective of this fundraising was to bolster its expansion plans, specifically for its high-value Steriport and SVP brands. This infusion of capital has been instrumental in deleveraging the company's balance sheet and setting the stage for future growth.

Financial Deep Dive: Numbers Tell a Story of Transformation

The Numbers

For the fiscal year ended March 31, 2025 (FY25), Amanta Healthcare reported operating income of ₹274.71 crore. While this represents a slight dip of 2% from ₹280.34 crore in FY24, the profitability picture is far brighter. Reported Profit After Tax (PAT) surged by an impressive 189% to ₹10.50 crore in FY25, up from ₹3.63 crore in FY24. Consequently, the PAT margin expanded significantly from 1.30% in FY24 to 3.82% in FY25.

Perhaps the most striking improvement is seen in the company's net worth, which jumped from ₹96 crore as of March 31, 2025, to ₹211 crore by September 30, 2025, largely due to the equity raised via the IPO.

The Quality

Amanta Healthcare's financial risk profile has transformed. The Adjusted Debt to Adjusted Networth ratio plummeted from 2.02 times in FY25 to a much healthier 0.84 times by September 30, 2025. Similarly, the Total Outside Liabilities to Adjusted Networth (TOLANW) ratio improved substantially from 2.99x to 1.32x, indicating a significant reduction in financial leverage.

Despite these improvements, the company's operations remain working capital intensive. Gross Current Assets (GCAs) typically span 170-180 days, with inventory holding periods between 90-110 days and receivables at 60-65 days. Liquidity is assessed as adequate, with bank limit utilization at a reasonable 58.37% for the 11 months ending October 31, 2025. Projected annual cash accruals of ₹40-45 crore comfortably cover yearly term debt obligations of ₹21-22 crore.

Risks & Outlook: The Road Ahead

Specific Risks

A key area for investors to monitor is the company's ambitious target for operating margins. Management guidance points to stable operating margins in the range of 21-22%, a substantial leap from the current reported PAT margins. Achieving this significant expansion will require flawless execution of expansion plans and strategic product mix management. The inherently working capital-intensive nature of the business also demands continuous efficiency in managing inventory and receivables to ensure robust cash flow.

The Forward View

CRISIL has assigned a 'Stable' outlook, reflecting confidence in Amanta Healthcare's established position in the parenteral segment. The company's strategy is focused on leveraging its capacity expansions for Steriport and SVP brands, which are slated to commence from April 2026. This expansion is anticipated to be the primary driver for healthy medium-term revenue growth, projected by CRISIL at 8-10% in fiscal 2026. The sustained revenue growth and successful achievement of its guided operating margins will be critical determinants of the company's ongoing financial health and market competitiveness.

Peer Comparison: Navigating a Competitive Landscape

Amanta Healthcare operates within the dynamic and competitive pharmaceutical sector, particularly in the parenteral (injectable) drug market. Key listed peers in this space include Gujarat Parenterals Limited (GPL), which also specializes in sterile injectables, and Strides Pharma Science Limited, a larger entity with a significant footprint in injectables. Historically, Amanta Healthcare has contended with higher leverage and lower margins compared to some peers. The recent IPO and subsequent deleveraging have marked a significant shift, improving its credit profile. Gujarat Parenterals, for instance, has generally maintained healthier operating margins and a more stable leverage profile. Strides Pharma Science, despite its larger scale, has also been implementing its own turnaround strategies. Amanta's future success hinges on its ability to effectively execute its expansion plans and realize its projected margin improvements to carve out a stronger position against these established competitors.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.